Mitchell Kapoor
Stock Analyst at HC Wainwright & Co.
(2.03)
# 3,056
Out of 4,981 analysts
346
Total ratings
37.99%
Success rate
-7.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $65 → $80 | $57.84 | +38.31% | 5 | Aug 7, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $72 → $75 | $76.33 | -1.74% | 37 | Aug 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $50 → $65 | $61.10 | +6.38% | 5 | Jul 31, 2025 | |
| ALMS Alumis | Reiterates: Buy | $14 | $4.38 | +219.63% | 13 | Jul 25, 2025 | |
| KRRO Korro Bio | Reiterates: Buy | $100 | $31.35 | +218.98% | 13 | Jul 24, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Buy | $45 | $15.26 | +194.89% | 6 | Jul 23, 2025 | |
| LEGN Legend Biotech | Reiterates: Buy | $75 | $33.88 | +121.37% | 39 | Jul 17, 2025 | |
| TYRA Tyra Biosciences | Reiterates: Buy | $30 | $12.31 | +143.70% | 20 | Jul 1, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $44 | $18.94 | +132.31% | 14 | Jul 1, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Sell | $40 → $10 | $17.47 | -42.76% | 14 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1 → $10 | $13.09 | -23.61% | 13 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $11.57 | +159.29% | 4 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $125 | $25.78 | +384.87% | 17 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $10.14 | +47.93% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.15 | +334.78% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $5 | $3.91 | +27.88% | 7 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.99 | +151.26% | 10 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $15 | $5.38 | +178.81% | 8 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $45 | $17.53 | +156.70% | 15 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $2.67 | +12.36% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $9.79 | +308.58% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.59 | - | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $7 | $1.82 | +284.62% | 9 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.92 | +56.25% | 6 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $2 | $0.50 | +302.25% | 16 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $0.49 | +1,744.64% | 15 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $5.73 | +162.01% | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.35 | - | 12 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40,000 → $610,000 | $0.99 | +61,491,835.48% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $6.72 | - | 4 | Jun 2, 2023 |
CRISPR Therapeutics AG
Aug 7, 2025
Maintains: Buy
Price Target: $65 → $80
Current: $57.84
Upside: +38.31%
Halozyme Therapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $76.33
Upside: -1.74%
Ionis Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $50 → $65
Current: $61.10
Upside: +6.38%
Alumis
Jul 25, 2025
Reiterates: Buy
Price Target: $14
Current: $4.38
Upside: +219.63%
Korro Bio
Jul 24, 2025
Reiterates: Buy
Price Target: $100
Current: $31.35
Upside: +218.98%
Oruka Therapeutics
Jul 23, 2025
Reiterates: Buy
Price Target: $45
Current: $15.26
Upside: +194.89%
Legend Biotech
Jul 17, 2025
Reiterates: Buy
Price Target: $75
Current: $33.88
Upside: +121.37%
Tyra Biosciences
Jul 1, 2025
Reiterates: Buy
Price Target: $30
Current: $12.31
Upside: +143.70%
Summit Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $44
Current: $18.94
Upside: +132.31%
Sarepta Therapeutics
Jun 25, 2025
Downgrades: Sell
Price Target: $40 → $10
Current: $17.47
Upside: -42.76%
Jun 24, 2025
Maintains: Neutral
Price Target: $1 → $10
Current: $13.09
Upside: -23.61%
Jun 16, 2025
Reiterates: Buy
Price Target: $30
Current: $11.57
Upside: +159.29%
Jun 5, 2025
Reiterates: Buy
Price Target: $125
Current: $25.78
Upside: +384.87%
Jun 2, 2025
Assumes: Buy
Price Target: $15
Current: $10.14
Upside: +47.93%
Jun 2, 2025
Initiates: Buy
Price Target: $5
Current: $1.15
Upside: +334.78%
May 27, 2025
Upgrades: Buy
Price Target: $4 → $5
Current: $3.91
Upside: +27.88%
May 20, 2025
Reiterates: Buy
Price Target: $5
Current: $1.99
Upside: +151.26%
May 16, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $5.38
Upside: +178.81%
May 13, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $17.53
Upside: +156.70%
Apr 28, 2025
Initiates: Buy
Price Target: $3
Current: $2.67
Upside: +12.36%
Apr 9, 2025
Reiterates: Buy
Price Target: $40
Current: $9.79
Upside: +308.58%
Apr 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.59
Upside: -
Apr 3, 2025
Maintains: Buy
Price Target: $14 → $7
Current: $1.82
Upside: +284.62%
Apr 3, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.92
Upside: +56.25%
Apr 3, 2025
Maintains: Buy
Price Target: $5 → $2
Current: $0.50
Upside: +302.25%
Apr 3, 2025
Reiterates: Buy
Price Target: $9
Current: $0.49
Upside: +1,744.64%
Mar 24, 2025
Reiterates: Buy
Price Target: $15
Current: $5.73
Upside: +162.01%
Dec 16, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -
Sep 6, 2023
Maintains: Buy
Price Target: $40,000 → $610,000
Current: $0.99
Upside: +61,491,835.48%
Jun 2, 2023
Reiterates: Neutral
Price Target: n/a
Current: $6.72
Upside: -